Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Newron Pharmaceuticals SpA ( (CH:NWRN) ) is now available.
Newron Pharmaceuticals announced upcoming changes to its Board of Directors ahead of the 23 April 2026 Annual General Meeting, with long‑serving members Patrick Langlois and company founder and former CEO Luca Benatti not standing for re‑election. To replace them, the company will propose industry veteran Dr. George Garibaldi and capital markets specialist Paolo Zocchi as new independent, non‑executive directors, aiming to bolster clinical neuroscience and financial governance expertise.
Management praised the departing directors for their strategic contributions, including Benatti’s role in developing Parkinson’s drug Xadago, and highlighted how the new nominees’ backgrounds in CNS drug development and complex international transactions are expected to complement the existing board. The full AGM agenda, along with 2025 financial results and 2026 outlook, will be published on 24 March 2026, signaling that governance refresh and strategic planning are being closely aligned as Newron advances its late‑stage schizophrenia program and broader growth ambitions.
The most recent analyst rating on (CH:NWRN) stock is a Hold with a CHF21.50 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company specializing in novel therapies for central and peripheral nervous system diseases, with headquarters in Bresso near Milan, Italy. Its lead candidate, Evenamide, is in a global phase III program for treatment‑resistant and poorly responsive schizophrenia, while its first marketed product, Xadago for Parkinson’s disease, is approved across major markets and commercialized through regional partners.
Average Trading Volume: 149,175
Technical Sentiment Signal: Buy
Current Market Cap: CHF338M
Find detailed analytics on NWRN stock on TipRanks’ Stock Analysis page.